基于视频的人工智能生物标志物用于主动脉瓣狭窄进展与结局的队列研究
该多队列研究将视频AI生物标志物DASSi应用于基线无重度主动脉瓣狭窄的患者,发现基线DASSi较高与主动脉瓣峰值流速年化进展更快及远期主动脉瓣置换风险升高独立相关,并在心脏磁共振队列中得以重现。
要点
- DASSi每增加0.1,主动脉瓣峰值流速年化进展在YNHHS队列为0.033 m/s(95%CI 0.028-0.038),CSMC队列为0.082 m/s(95%CI 0.053-0.111)。
- DASSi≥0.2者远期主动脉瓣置换风险显著高于<0.2者(YNHHS调整HR 4.97,95%CI 2.71-5.82;CSMC调整HR 4.04,95%CI 0.92-17.70)。
- 在UK Biobank心脏磁共振队列中,DASSi≥0.2者主动脉瓣置换风险亦显著升高(调整HR 11.38,95%CI 2.56-50.57)。
核心结论
- 在无重度主动脉瓣狭窄的队列中,基于视频的AI生物标志物DASSi与主动脉瓣狭窄的进展和远期主动脉瓣置换独立相关,可跨影像模态进行机会性风险分层。
主要发现
- 基线DASSi较高与主动脉瓣峰值流速年化进展更快相关:YNHHS队列每0.1 DASSi增量对应0.033 m/s/年(95%CI 0.028-0.038,n=5483),CSMC队列对应0.082 m/s/年(95%CI 0.053-0.111,n=1292)。
- DASSi≥0.2与远期主动脉瓣置换风险升高相关:YNHHS队列715例事件,调整HR 4.97(95%CI 2.71-5.82);CSMC队列56例事件,调整HR 4.04(95%CI 0.92-17.70)。
- 上述关联独立于年龄、性别、种族、民族、射血分数和主动脉瓣峰值流速。
- UK Biobank心脏磁共振队列中,DASSi≥0.2者相比DASSi<0.02者,主动脉瓣置换调整HR为11.38(95%CI 2.56-50.57)。
- 显著性图和全表型关联研究支持DASSi与心脏结构功能及传统心血管危险因素相关。
临床怎么用
- DASSi可基于单视角长轴超声心动图视频(无需多普勒)计算,有望用于无重度主动脉瓣狭窄患者的机会性风险分层。
- DASSi值较高(如≥0.2)提示主动脉瓣狭窄进展和远期主动脉瓣置换风险增加,可辅助个体化随访策略。
- 该生物标志物可跨超声和心脏磁共振模态应用,并具备手持设备部署潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Aortic stenosis (AS) is a major public health challenge with a growing therapeutic landscape, but current biomarkers do not inform personalized screening and follow-up. A video-based artificial intelligence (AI) biomarker (Digital AS Severity index [DASSi]) can detect severe AS using single-view long-axis echocardiography without Doppler characterization. OBJECTIVE: To deploy DASSi to patients with no AS or with mild or moderate AS at baseline to identify AS development and progression. DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study that examined 2 cohorts of patients without severe AS undergoing echocardiography in the Yale New Haven Health System (YNHHS; 2015-2021) and Cedars-Sinai Medical Center (CSMC; 2018-2019). A novel computational pipeline for the cross-modal translation of DASSi into cardiac magnetic resonance (CMR) imaging was further developed in the UK Biobank. Analyses were performed between August 2023 and February 2024. EXPOSURE: DASSi (range, 0-1) derived from AI applied to echocardiography and CMR videos. MAIN OUTCOMES AND MEASURES: Annualized change in peak aortic valve velocity (AV-Vmax) and late (>6 months) aortic valve replacement (AVR). RESULTS: A total of 12 599 participants were included in the echocardiographic study (YNHHS: n = 8798; median [IQR] age, 71 [60-80] years; 4250 [48.3%] women; median [IQR] follow-up, 4.1 [2.4-5.4] years; and CSMC: n = 3801; median [IQR] age, 67 [54-78] years; 1685 [44.3%] women; median [IQR] follow-up, 3.4 [2.8-3.9] years). Higher baseline DASSi was associated with faster progression in AV-Vmax (per 0.1 DASSi increment: YNHHS, 0.033 m/s per year [95% CI, 0.028-0.038] among 5483 participants; CSMC, 0.082 m/s per year [95% CI, 0.053-0.111] among 1292 participants), with values of 0.2 or greater associated with a 4- to 5-fold higher AVR risk than values less than 0.2 (YNHHS: 715 events; adjusted hazard ratio [HR], 4.97 [95% CI, 2.71-5.82]; CSMC: 56 events; adjusted HR, 4.04 [95% CI, 0.92-17.70]), independent of age, sex, race, ethnicity, ejection fraction, and AV-Vmax. This was reproduced across 45 474 participants (median [IQR] age, 65 [59-71] years; 23 559 [51.8%] women; median [IQR] follow-up, 2.5 [1.6-3.9] years) undergoing CMR imaging in the UK Biobank (for participants with DASSi ≥0.2 vs those with DASSi <.02, adjusted HR, 11.38 [95% CI, 2.56-50.57]). Saliency maps and phenome-wide association studies supported associations with cardiac structure and function and traditional cardiovascular risk factors. CONCLUSIONS AND RELEVANCE: In this cohort study of patients without severe AS undergoing echocardiography or CMR imaging, a new AI-based video biomarker was independently associated with AS development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.
引用
- Oikonomou EK, Holste G, Yuan N, et al. A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression. JAMA Cardiol. 2024. PMID: 38581644. doi:10.1001/jamacardio.2024.0595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。